Catalyst

Slingshot members are tracking this event:

Tobira's Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TBRA

100%

Additional Information

Additional Relevant Details The results from this study have been published in the journal PLOS ONE(http://dx.doi.org/10.1371/journal.pone.0158156)."These data show that CVC displayed significant anti-inflammatory and anti-fibrotic effects across a range of in vivo models, including non-alcoholic steatohepatitis (NASH), liver and kidney fibrosis models. These findings support CVC's anti-inflammatory and anti-fibrotic mechanism of action, and are further substantiated by results from a diet-induced NASH model, where CVC-treated animals had significantly less liver fibrosis and decreased lobular inflammation and hepatocellular ballooning, the hallmark features of NASH, relative to untreated animals," said Scott Friedman, M.D., chief,Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, and lead author. "The comprehensive and consistent preclinical data demonstrating the potent anti-inflammatory and anti-fibrotic effects of CVC enabled its clinical development in patients with NASH and fibrosis.""We are excited about the publication of these translational data which substantiate CVC's potential to address a serious medical condition like fibrotic NASH. With the top-line primary analysis results of our Phase 2b CENTAUR study expected in the third quarter of 2016, this is a transformative time for Tobira as we continue to build our NASH program and prepare for Phase 3," said Eric Lefebvre, M.D., chief medical officer of Tobira.
http://ir.tobiratx.c...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 27, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2b Centaur, Nash, Kidney Disease, Chronic Liver Disease, Inflammation